Influence of Extraperitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases

Article Surgery

Prehabilitation before major abdominal surgery: Evaluation of the impact of a perioperative clinical pathway, a pilot study

Ilies E. Boukili et al.

Summary: The study evaluated the feasibility and safety of a prehabilitation program before major abdominal surgery. The results showed that prehabilitation can improve patients' functional reserves, quality of life, and psychological status.

SCANDINAVIAN JOURNAL OF SURGERY (2022)

添加到收藏夹

Article Oncology

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Phis Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO

Daniele Rossini et al.

Summary: The intensification of upfront chemotherapy backbone with panitumumab does not provide additional benefit in terms of treatment activity in patients with RAS and BRAF wt mCRC, while increasing gastrointestinal toxicity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI)

R. Lo Dico et al.

EJSO (2021)

添加到收藏夹

Review Health Care Sciences & Services

The multidisciplinary management of oligometastases from colorectal cancer: a narrative review

Edward T. J. Chandy et al.

Summary: In the United States, it is estimated that nearly 150,000 people will be diagnosed with colorectal cancer in 2020, with up to 35% expected to present with oligometastatic disease; five-year survival rates of up to 42% can be achieved through surgery for solitary lesions.

ANNALS OF PALLIATIVE MEDICINE (2021)

添加到收藏夹

Article Oncology

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial

Francois Quenet et al.

Summary: This study aimed to evaluate the specific benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery compared with receiving cytoreductive surgery alone in patients with colorectal peritoneal metastases. The results showed no significant overall survival benefit after adding HIPEC, with more frequent postoperative late complications, suggesting that cytoreductive surgery alone should be prioritized as a treatment strategy.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT

Meritxell Molla et al.

Summary: The prognosis for oligometastatic colorectal cancer has improved due to recent advances in new techniques and approaches such as new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy. Factors to consider when deciding on the best approach include tumor factors, patient factors, and physician factors. These advances have presented challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Treatment Strategies and Prognosis of Patients With Synchronous or Metachronous Colorectal Peritoneal Metastases: A Population-Based Study

C. Bakkers et al.

Summary: The study compared treatment strategies and survival in patients with synchronous and metachronous colorectal peritoneal metastases. Overall survival did not significantly differ between patients with synchronous and metachronous CPM, suggesting a similar prognosis regardless of the onset of CPM.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology